ANKMY1

Across TCGA pan-cancer cohorts, ANKMY1 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated ANKMY1 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher ANKMY1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANKMY1 expression acts as an unfavorable survival marker.

LGG, SARC, and PRAD are the cancer types where ANKMY1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	DFS	Median	All	0.148	0.739	<.001	12	view →
SARC	DFS	Median	All	0.163	0.517	.037	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	OS	Median	III,IV	0.112	0.664	.003	6	view →
THCA	OS	Median	All	0.277	0.954	<.001	4	view →
KIRP	OS	Median	II,III,IV	0.199	0.771	.030	4	view →
COAD	DFS	Median	II,III,IV	0.177	0.563	.019	4	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
BLCA	DFS	Median	IV	0.083	0.476	.001	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
LIHC	OS	Median	All	0.177	0.783	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

ANKMY1–LGG (DFS)

Open the LGG breakdown →